Advertisement

Hepatobiliäre Erkrankungen bei HIV-Infizierten

  • H. Dancygier
Chapter

Zusammenfassung

Prinzipiell können bei HIV-Infizierten alle Lebererkrankungen auftreten, die auch bei HIV-negativen Personen beobachtet werden. Gleichwohl schaffen die zunehmende Immundefizienz und hochdosierte anti-retrovirale Kombinationstherapien eine besondere Situation, in der charakteristische hepatobiliäre Veränderungen auftreten können. Die Art der hepatischen Reaktion und des Leberschädens hängt weitgehend vom Stadium der Immundefizienz ab. Lebererkrankungen bei HIV-Infizierten mit noch normalem Immunstatus weisen keine Unterschiede gegenüber immunkompetenten Normalpersonen auf. AIDS-Patienten hingegen entwickeln ein besonderes Spektrum hepatobiliärer Erkrankungen. Es handelt sich in erster Linie um
  • Infektionen,

  • Neoplasien und

  • medikamentöse Leberschäden.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Bessesen M, Ives D, Condreay L et al. (1999) Chronic active hepatitis B exacerbations in human immunodeficiency virusi-nfected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 28: 1032–1035PubMedCrossRefGoogle Scholar
  2. Benahmou Y, Bochet M, Di Martino V et al. (1999) Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The multivir group. Hepatology 30: 1054–1058CrossRefGoogle Scholar
  3. Benhamou Y, Bochet M, Thibault V et al. (1999) Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 30: 1302–1306PubMedCrossRefGoogle Scholar
  4. Benhamou Y, Di Martino V, Bochet M et al. (2001) Factors affecting liver fibrosis in human immunodeficiency virusand hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 34: 283–287PubMedCrossRefGoogle Scholar
  5. Bodsworth N, Donovan B, Nightingale BN (1989) The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis 160: 577–582PubMedCrossRefGoogle Scholar
  6. Bonacini M, Puoti M (2000) Hepatitis C in patients with human immunodeficiency virus infection. Arch Intern Med 160:3365–3373CrossRefGoogle Scholar
  7. Cappell MS, Schwartz MS, Biemipca L (1990) Clinical utility of liver biopsy in patients with serum antibodies to the human immunodeficiency virus. Am J Med 88: 123–130PubMedCrossRefGoogle Scholar
  8. Carr A, Miller J, Law M et al. (2000) A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 14: 25–32CrossRefGoogle Scholar
  9. Causse X, Payen JL, Izopet J et al. (2000) Does HIV-infection influence the response of chronic hepatitis C to interferon treatment? A French multicenter prospective study. J Hepatol 32: 1003–1010PubMedCrossRefGoogle Scholar
  10. Colin JF, Cazals-Hatem D, Loriot MA et al. (1999) Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 29: 1306–1310PubMedCrossRefGoogle Scholar
  11. Eyster ME, Diamondstone LS, Lien JM et al. (1993) Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The multicenter hemophilia cohort study. J Acquir Immune Defic Syndr Hum Retrovirol 6: 602–610Google Scholar
  12. Greub G, Ledergerber B, Battegay Met al. (2000) Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection. The Swiss HIV cohort study. Lancet 356: 1800–1805PubMedCrossRefGoogle Scholar
  13. Hadler SC, Judson FN, O’Malley PM et al. (1991) Outcome of hepatitis B virus infection in homosexual men and its relationship to prior human immunodeficiency virus infection. J Infect Dis 162: 454–459CrossRefGoogle Scholar
  14. Lafeuillade A, Hittinger G, Chadapaud S (2001) Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 357: 280–281PubMedCrossRefGoogle Scholar
  15. Lichterfeld M, Spengler U, Rockstroh J (2001) Hepatotoxizität der antiretroviralen Therapie. Arzneimitteltherapie 19: 250–258Google Scholar
  16. Poles MA, Dieterich DT, Schwarz ED et al. (1996) Liver biopsy findings in 501 patients infected with human immunodeficiency virus (HIV). J Acquir Immune Defic Syndr Hum Retrovirol 11: 170–177PubMedCrossRefGoogle Scholar
  17. Poles MA, Dieterich DT (2000) Infections of the liver in HIV infected patients. Infect Dis Clin North Am 14: 741–759PubMedCrossRefGoogle Scholar
  18. Rutschmann OT, Negro F, Hirschel B et al. (1998) Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis 177: 783–785PubMedCrossRefGoogle Scholar
  19. Sauleda S, Juarez A, Esteban JI et al. (2001) Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders. Hepatology 34: 1035–1040PubMedCrossRefGoogle Scholar
  20. Servoss JC, Sherman KE, Robbins G et al. (2001) Hepatotoxicity in the US adult AIDS clinical trial group. Gastroenterology 120: A54Google Scholar
  21. Sherman KE, Rouster SD, Chung R et al. (2000) Hepatitis C prevalence in HIV-infected patients: a cross sectional analysis of the US adults AIDS clinical trials group. Antiviral Ther 5 [suppl 1]: 64Google Scholar
  22. Tillmann HL, Heiken H, Knapik-Botor A et al. (2001) Infection with GB virus C and reduced mortality among HIV-infected patients. N Engl J Med 345: 715–724PubMedCrossRefGoogle Scholar
  23. Xiang J, Wunschmann S, Diekema DJ et al. (2001) Effect of coinfection with GB virus C on survival among patients with HIV infection. N Engl J Med 345: 707–714PubMedCrossRefGoogle Scholar
  24. Zylberberg H, Benhamou Y, Lagneaux JL et al. (2000) Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut 47: 694–697PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • H. Dancygier

There are no affiliations available

Personalised recommendations